MX2020002646A - Inhibidores de enpp1 y su uso para el tratamiento del cancer. - Google Patents
Inhibidores de enpp1 y su uso para el tratamiento del cancer.Info
- Publication number
- MX2020002646A MX2020002646A MX2020002646A MX2020002646A MX2020002646A MX 2020002646 A MX2020002646 A MX 2020002646A MX 2020002646 A MX2020002646 A MX 2020002646A MX 2020002646 A MX2020002646 A MX 2020002646A MX 2020002646 A MX2020002646 A MX 2020002646A
- Authority
- MX
- Mexico
- Prior art keywords
- enpp1
- subject
- cancer
- methods
- inhibitor
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 6
- 201000011510 cancer Diseases 0.000 title abstract 5
- 239000003112 inhibitor Substances 0.000 title abstract 5
- 101150017770 ENPP1 gene Proteins 0.000 title 1
- 101000812677 Homo sapiens Nucleotide pyrophosphatase Proteins 0.000 abstract 6
- 102100039306 Nucleotide pyrophosphatase Human genes 0.000 abstract 6
- 238000000034 method Methods 0.000 abstract 6
- 239000000203 mixture Substances 0.000 abstract 2
- 238000001959 radiotherapy Methods 0.000 abstract 2
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- RFCBNSCSPXMEBK-INFSMZHSSA-N c-GMP-AMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]3[C@@H](O)[C@H](N4C5=NC=NC(N)=C5N=C4)O[C@@H]3COP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 RFCBNSCSPXMEBK-INFSMZHSSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229940127089 cytotoxic agent Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000007062 hydrolysis Effects 0.000 abstract 1
- 238000006460 hydrolysis reaction Methods 0.000 abstract 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 230000005855 radiation Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/16—Esters of thiophosphoric acids or thiophosphorous acids
- C07F9/165—Esters of thiophosphoric acids
- C07F9/1651—Esters of thiophosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3826—Acyclic unsaturated acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/44—Amides thereof
- C07F9/4403—Amides thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4407—Amides of acyclic saturated acids which can have further substituents on alkyl
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se proporcionan compuestos, composiciones y métodos para la inhibición de ENPP1. Aspectos de los métodos de la presente incluyen poner en contacto una muestra con un inhibidor de ENPP1 para inhibir la actividad de hidrólisis de cGAMP de ENPP1. En algunos casos, el inhibidor de ENPP1 es impermeable a las células. También se proporcionan composiciones y métodos para tratar el cáncer. Aspectos de los métodos incluyen administrarle a un sujeto una cantidad terapéuticamente eficaz de un inhibidor de ENPP1 para tratar el cáncer del sujeto. En determinados casos, el cáncer es un cáncer de tumor sólido. También se proporcionan métodos para administrar radioterapia a un sujeto ya sea antes o después de administrar un inhibidor de ENPP1. La radioterapia puede administrarse a una dosificación y/o frecuencia eficaz para reducir el daño de radiación al sujeto. En determinados casos, el método se realiza en combinación con un agente quimioterapéutico, o un inhibidor del punto de control o ambos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762556117P | 2017-09-08 | 2017-09-08 | |
| PCT/US2018/050018 WO2019051269A1 (en) | 2017-09-08 | 2018-09-07 | ENPP1 INHIBITORS AND THEIR USE FOR THE TREATMENT OF CANCER |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020002646A true MX2020002646A (es) | 2020-09-25 |
Family
ID=63714052
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020002646A MX2020002646A (es) | 2017-09-08 | 2018-09-07 | Inhibidores de enpp1 y su uso para el tratamiento del cancer. |
| MX2023007193A MX2023007193A (es) | 2017-09-08 | 2020-03-06 | Inhibidores de enpp1 y su uso para el tratamiento del cancer. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023007193A MX2023007193A (es) | 2017-09-08 | 2020-03-06 | Inhibidores de enpp1 y su uso para el tratamiento del cancer. |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US11701371B2 (es) |
| EP (2) | EP4327882A3 (es) |
| JP (2) | JP7292740B2 (es) |
| KR (1) | KR20200066292A (es) |
| CN (2) | CN111372587B (es) |
| AU (2) | AU2018330188C1 (es) |
| BR (1) | BR112020004559A2 (es) |
| CA (1) | CA3074268A1 (es) |
| DK (1) | DK3678668T3 (es) |
| EA (1) | EA202090595A1 (es) |
| IL (3) | IL302338A (es) |
| MA (1) | MA50082A (es) |
| MX (2) | MX2020002646A (es) |
| SG (1) | SG11202001728YA (es) |
| WO (1) | WO2019051269A1 (es) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220056052A1 (en) * | 2018-12-28 | 2022-02-24 | Riboscience Llc | Quinazoline derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors |
| KR20220117927A (ko) | 2019-09-16 | 2022-08-24 | 아텐 포러스 라이프사이언시즈 피브이티. 리미티드 | Enpp1 단백질 억제제로서의 2-아미노-s6-치환된 티오퓨린 화합물 |
| CN115151253A (zh) * | 2019-09-23 | 2022-10-04 | 南京征祥医药有限公司 | 磷酸二酯酶抑制剂及用途 |
| EP4100394A1 (en) * | 2020-02-04 | 2022-12-14 | Stingray Therapeutics, Inc. | Inhibitors of ectonucleotide pyrophosphatase/phosphodiesterase 1 (enpp1) and methods of use thereof |
| TWI794742B (zh) | 2020-02-18 | 2023-03-01 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| WO2021203772A1 (en) * | 2020-04-09 | 2021-10-14 | Betta Pharmaceuticals Co., Ltd | Ectonucleotide pyrophosphatase-phosphodiesterase 1 inhibitors,compositions and uses thereof |
| TW202208337A (zh) * | 2020-05-04 | 2022-03-01 | 美商佛拉斯托醫療公司 | Ｅｎｐｐ１之亞胺基硫烷酮抑制劑 |
| WO2021225407A1 (ko) | 2020-05-08 | 2021-11-11 | 주식회사 티씨노바이오사이언스 | 엑토뉴클레오티드 피로포스파타아제-포스포디에스터라아제의 저해 활성을 갖는 신규한 프탈라진 유도체 및 이들의 용도 |
| KR20210136874A (ko) | 2020-05-08 | 2021-11-17 | 주식회사 티씨노바이오사이언스 | 엑토뉴클레오티드 피로포스파타아제-포스포디에스터라아제의 저해 활성을 갖는 신규한 프탈라진 유도체 및 이들의 용도 |
| WO2021257614A1 (en) * | 2020-06-16 | 2021-12-23 | Volastra Therapeutics, Inc. | Heterocyclic inhibitors of enpp1 |
| KR20230062845A (ko) * | 2020-09-03 | 2023-05-09 | 이뮨센서 테라퓨틱스, 인코포레이티드 | 퀴놀린 cgas 길항제 화합물 |
| KR20230118602A (ko) * | 2020-12-09 | 2023-08-11 | 스팅레이 테라퓨릭스, 인크. | Enpp1 및 cdnp의 억제제로서의 포스포네이트 |
| KR20220095154A (ko) | 2020-12-29 | 2022-07-06 | 주식회사 티씨노바이오사이언스 | 엑토뉴클레오티드 피로포스파타아제-포스포디에스터라아제의 저해 활성을 갖는 신규한 나프티리딘온 유도체 및 이들의 용도 |
| EP4276100A1 (en) | 2020-12-29 | 2023-11-15 | Txinno Bioscience Inc. | Novel naphthyridinone derivative having inhibitory activity against ectonucleotide pyrophosphatase-phosphodiesterase and use thereof |
| KR20220110118A (ko) | 2021-01-29 | 2022-08-05 | 주식회사 티씨노바이오사이언스 | 엑토뉴클레오티드 피로포스파타아제-포스포디에스터라아제의 저해 활성을 갖는 신규한 벤조트리아졸 유도체 및 이들의 용도 |
| EP4286374A1 (en) | 2021-01-29 | 2023-12-06 | Txinno Bioscience Inc. | Novel benzotriazole derivative having inhibitory activity against ectonucleotide pyrophosphatase-phosphodiesterase, and use thereof |
| WO2022197734A1 (en) * | 2021-03-16 | 2022-09-22 | Riboscience Llc | Bicyclic heteroaryl boronate derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors |
| US11697666B2 (en) | 2021-04-16 | 2023-07-11 | Gilead Sciences, Inc. | Methods of preparing carbanucleosides using amides |
| CN115536696B (zh) * | 2021-06-29 | 2023-07-14 | 上海齐鲁制药研究中心有限公司 | Enpp1抑制剂 |
| WO2023035001A1 (en) * | 2021-09-03 | 2023-03-09 | Angarus Therapeutics, Inc. | Enpp1 inhibitors and immune cells expressing chimeric antigen receptors |
| WO2023077083A1 (en) * | 2021-10-29 | 2023-05-04 | Angarus Therapeutics, Inc. | Enpp1 inhibitors as inhibitors of metastasis |
| WO2023197987A1 (zh) * | 2022-04-11 | 2023-10-19 | 上海齐鲁制药研究中心有限公司 | Enpp1抑制剂 |
| CN114767863B (zh) * | 2022-04-29 | 2024-01-30 | 西北工业大学 | 一种enpp2基因或蛋白在调控结直肠癌细胞中的应用 |
| US20230346771A1 (en) | 2022-04-29 | 2023-11-02 | Petragen, Inc. | Inhibitors of enpp1 and modulation of bone growth |
| WO2024028727A1 (en) * | 2022-08-01 | 2024-02-08 | Sravathi Ai Technology Private Limited | Novel ectonucleotide pyrophosphatase / phosphodiesterase 1 (enpp-1) inhibitors and uses thereof |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA228044A (en) | 1923-01-16 | Thomas Noble Boughton | Die for forming bolts | |
| CA190896A (en) | 1919-02-24 | 1919-06-17 | Josephat C. Bergeron | Advertising device |
| DE3319795A1 (de) | 1983-06-01 | 1984-12-06 | Hoechst Ag, 6230 Frankfurt | Verfahren zur herstellung von phosphonsaeureestern |
| US5599902A (en) | 1994-11-10 | 1997-02-04 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Cancer inhibitory peptides |
| ES2150664T3 (es) | 1995-04-21 | 2000-12-01 | Teikoku Hormone Mfg Co Ltd | Nuevos derivados peptidos. |
| US6323315B1 (en) | 1999-09-10 | 2001-11-27 | Basf Aktiengesellschaft | Dolastatin peptides |
| WO2002072578A2 (en) | 2001-03-08 | 2002-09-19 | Millennium Pharmaceuticals | (homo) piperazine substituted quinolines for inhibiting the phosphorylation of kinases |
| EP1391213A1 (en) | 2002-08-21 | 2004-02-25 | Boehringer Ingelheim International GmbH | Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents |
| EP1578755B1 (en) | 2002-12-24 | 2007-08-22 | AstraZeneca AB | Phosphonooxy quinazoline derivatives and their pharmaceutical use |
| US20070004763A1 (en) | 2005-06-10 | 2007-01-04 | Nand Baindur | Aminoquinoline and aminoquinazoline kinase modulators |
| US10543207B2 (en) | 2008-12-31 | 2020-01-28 | Ardelyx, Inc. | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
| EP2621923B1 (en) | 2010-09-29 | 2017-03-29 | Intervet International B.V. | N-heteroaryl compounds with cyclic bridging unit for the treatment of parasitic diseases |
| EP2794630A4 (en) | 2011-12-22 | 2015-04-01 | Alios Biopharma Inc | SUBSTITUTED PHOSPHORTHIOAT NUCLEOTIDE ANALOGUE |
| WO2014179760A1 (en) | 2013-05-03 | 2014-11-06 | The Regents Of The University Of California | Cyclic di-nucleotide induction of type i interferon |
| MX354057B (es) | 2013-05-18 | 2018-02-09 | The Regents Of The Univ Of California Star | Composiciones y métodos para activar la señalización dependiente del "estimulador del gene de interferón". |
| AU2015321654B2 (en) * | 2014-09-22 | 2019-10-31 | National Health Research Institutes | Heterocyclic compounds and use thereof |
| US10011600B2 (en) | 2014-09-25 | 2018-07-03 | Araxes Pharma Llc | Methods and compositions for inhibition of Ras |
| CN105153153A (zh) | 2015-08-31 | 2015-12-16 | 吉林奥来德光电材料股份有限公司 | 一种新的芳香族胺类化合物及其制备与应用 |
| TWI659949B (zh) | 2016-05-16 | 2019-05-21 | 臺北醫學大學 | 組蛋白去乙醯酶6抑制劑及其用途 |
| KR20190126761A (ko) | 2016-12-22 | 2019-11-12 | 마브파마, 인크. | Ｉ형 ｉｆｎ 생산을 증강 또는 증대하는 조성물 및 방법 |
| US20190327974A1 (en) | 2017-01-09 | 2019-10-31 | The Australian National University | Synergists for improved pesticides |
| US10518257B2 (en) | 2017-05-04 | 2019-12-31 | Exxonmobil Research And Engineering Company | Metal organic frameworks, their synthesis and use |
| WO2018229139A1 (en) | 2017-06-14 | 2018-12-20 | Fundación Para La Investigación Médica Aplicada | Novel compounds for use in cancer |
| CN111315723A (zh) | 2017-08-31 | 2020-06-19 | 艾伯维公司 | 膜外核苷酸焦磷酸酶-磷酸二酯酶1(enpp-1)抑制剂及其用途 |
| WO2020160333A1 (en) | 2019-02-01 | 2020-08-06 | The Board Of Trustees Of The Leland Stanford Junior University | Enpp1 inhibitors and methods of modulating immune response |
| CN114437128B (zh) * | 2022-01-28 | 2023-12-19 | 中国科学院长春应用化学研究所 | 一种胆碱磷酸修饰的紫杉醇药物及其制备方法和应用 |
-
2018
- 2018-09-07 AU AU2018330188A patent/AU2018330188C1/en active Active
- 2018-09-07 WO PCT/US2018/050018 patent/WO2019051269A1/en active Application Filing
- 2018-09-07 EA EA202090595A patent/EA202090595A1/ru unknown
- 2018-09-07 IL IL302338A patent/IL302338A/en unknown
- 2018-09-07 IL IL272948A patent/IL272948B2/en unknown
- 2018-09-07 MX MX2020002646A patent/MX2020002646A/es unknown
- 2018-09-07 MA MA050082A patent/MA50082A/fr unknown
- 2018-09-07 KR KR1020207007008A patent/KR20200066292A/ko not_active Application Discontinuation
- 2018-09-07 JP JP2020513331A patent/JP7292740B2/ja active Active
- 2018-09-07 IL IL311010A patent/IL311010A/en unknown
- 2018-09-07 DK DK18779884.8T patent/DK3678668T3/da active
- 2018-09-07 BR BR112020004559-4A patent/BR112020004559A2/pt unknown
- 2018-09-07 EP EP24150802.7A patent/EP4327882A3/en active Pending
- 2018-09-07 EP EP18779884.8A patent/EP3678668B1/en active Active
- 2018-09-07 CA CA3074268A patent/CA3074268A1/en active Pending
- 2018-09-07 CN CN201880063793.8A patent/CN111372587B/zh active Active
- 2018-09-07 SG SG11202001728YA patent/SG11202001728YA/en unknown
- 2018-09-07 CN CN202311760294.3A patent/CN117883449A/zh active Pending
- 2018-09-07 US US16/645,300 patent/US11701371B2/en active Active
-
2020
- 2020-03-06 MX MX2023007193A patent/MX2023007193A/es unknown
-
2022
- 2022-09-30 US US17/957,392 patent/US11707471B2/en active Active
-
2023
- 2023-05-16 US US18/197,877 patent/US20230277570A1/en active Pending
- 2023-05-31 JP JP2023089900A patent/JP2023101715A/ja active Pending
-
2024
- 2024-01-10 AU AU2024200148A patent/AU2024200148A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023007193A (es) | Inhibidores de enpp1 y su uso para el tratamiento del cancer. | |
| MX2021009269A (es) | Inhibidores de enpp1 y metodos para modular una respuesta inmunitaria. | |
| MX2023002248A (es) | Uso de inhibidores de sos1 para tratar neoplasias malignas con mutaciones de shp2. | |
| PH12019502132A1 (en) | Combination therapy for the treatment or prevention of tumours | |
| MX2016008201A (es) | Tratamiento del cancer usando combinaciones de inhibidores de erk y raf. | |
| PH12016500841A1 (en) | Combinations of checkpoint inhibitors and therapeutics to treat cancer | |
| MX2021005651A (es) | Combinacion farmaceutica para el tratamiento contra el cancer. | |
| WO2018102687A3 (en) | Combination therapy for treating cancer | |
| EA201391286A1 (ru) | Лечение солидных опухолей | |
| MY183661A (en) | Treatment of cancer with tor kinase inhibitors | |
| PH12020551597A1 (en) | Treatment of hidradenitis suppurativa using jak inhibitors | |
| SG10201810401RA (en) | Pharmaceutical combinations for treating cancer | |
| EA201491699A1 (ru) | Лечение рака ингибиторами tor киназы | |
| WO2015095838A3 (en) | Cancer treatments using combinations of mek type i and erk inhibitors | |
| MX2021010173A (es) | Compuestos con actividad inductora de ferroptosis y métodos de uso. | |
| MX2020001727A (es) | Terapia de combinacion. | |
| MX2019013862A (es) | Terapia de combinacion. | |
| SG10201810575WA (en) | Treatment of prostate cancer with tor kinase inhibitors | |
| MX2022015900A (es) | Inhibidores de alk2 para el tratamiento de la anemia. | |
| MX2021007565A (es) | Composiciones y metodos para la terapia contra el cancer. | |
| ZA201901367B (en) | Inhibition of olig2 activity | |
| MX2018010223A (es) | Terapia combinada para tratamiento de cancer de ovario. | |
| MX2021006778A (es) | Metodo novedoso para el tratamiento del cancer mediante inmunomodulacion. | |
| MX2020006808A (es) | Ubicar al complejo de signalosoma cbm induce a las celulas t reguladoras inflamar al microambiente tumoral. | |
| MX2021005189A (es) | Uso de tivozanib para tratar sujetos con cancer refractario. |